ETFs Guardant Health, Inc.

GH

US40131M1099

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 21:00:00 17/02/2026 GMT			5-day change	1st Jan Change
107.11 ^USD	+2.16%		+1.98%	+4.87%

02-02	Guardant Health, Inc. Announces Publication of the Largest Study to Date Evaluating Circulating Tumors forMRD Detection in Patients with Rescted Stage III Colon Cancer After Surgery and Before Adjuvant Chemotherapy	CI
01-30	UBS Adjusts Price Target on Guardant Health to $175 From $110, Maintains Buy Rating	MT

ETFs positioned on Guardant Health, Inc.

Name	Varia. Jan 1.	Weight	AuM
LEVERAGE SHARES PLC - LS ARK GENOMIC REVOLUTION TRACKER ETP	-0.54%	1.22%	1 M€
ADAPTIVE GROWTH OPPORTUNITIES ETF - USD	+3.40%	0.02%	300 M€
VANGUARD US TOTAL MARKET SHARES INDEX ETF	-5.96%	0.01%	293,477 M€
STRATEGY SHARES NASDAQ 7HANDL INDEX ETF - USD	+2.50%	0%	549 M€

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Employees

2,010

Sector

Medical Equipment, Supplies & Distribution

Calendar

02-19 - Q4 2025 Earnings Release

More about the company